Is there a role for omacetaxine in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors?

Damlaj, Moussab; Assouline, Sarit

doi:10.3109/10428194.2014.918972

Search citation statements

Order By: Relevance

Paper Sections

Select...

Other1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2016

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar conclusions were drawn by other authors confirming that Omacetaxine mepesuccinate is beneficial even for some poor prognosis TKI-resistant CML patients [i.e. [43][44][45].…”

Section: Therapeutic Use Of Omacetaxine Mepesuccinate As Replacement supporting

confidence: 89%

Protein synthesis inhibitors of natural origin for CML therapy: semisynthetic homoharringtonine (Omacetaxine mepesuccinate)

Novotný¹,

Al‐Tannak²,

Hunáková³

2016

neo

View full text Add to dashboard Cite

Omacetaxine mepesuccinate is a drug approved in 2014 by FDA for the use in CML therapy in patients resistant to at least two thymidine kinase inhibitors (TKIs). It possesses unique mechanism of anticancer activity that is principally different from mechanism of activity of TKIs. Omacetaxine mepesuccinate inhibits protein translation through prevention of the initial elongation step of protein synthesis and its use benefits CML patients possessing the BCR-ABL oncogene. Because of the superior activity of Omacetaxine in patients who became resistant to therapy with TKIs, FDA decided on the accelerated approval of this drug taking its consideration not only its activity as such but also a favorable benefit-to-risk profile in patients included into clinical studies.

show abstract

“…Similar conclusions were drawn by other authors confirming that Omacetaxine mepesuccinate is beneficial even for some poor prognosis TKI-resistant CML patients [i.e. [43][44][45].…”

Section: Therapeutic Use Of Omacetaxine Mepesuccinate As Replacement supporting

confidence: 89%

Protein synthesis inhibitors of natural origin for CML therapy: semisynthetic homoharringtonine (Omacetaxine mepesuccinate)

Novotný¹,

Al‐Tannak²,

Hunáková³

2016

neo

View full text Add to dashboard Cite

show abstract

Is there a role for omacetaxine in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors?

Cited by 1 publication

References 14 publications

Protein synthesis inhibitors of natural origin for CML therapy: semisynthetic homoharringtonine (Omacetaxine mepesuccinate)

Protein synthesis inhibitors of natural origin for CML therapy: semisynthetic homoharringtonine (Omacetaxine mepesuccinate)

Contact Info

Product

Resources

About